Skip to main content

Table 3 Overall survival and progression free survival in all included trials

From: First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis

Study(C/B)

Median OS (Months)

Median PFS (Months)

 

C

B

C

B

Venook AP 2017

30

29

10.5

10.6

FIRE-32014

28.7

25

10

10.3

Houts AC 2017

30.64

31.04

10.19

10.82

Bai L 2016

28.3

27.7

8.7

10.6

2014 Yang YH

37.8

30.5

12.4

8.7

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us